WELL trades at a FY25 normalized P/E of 9.4, despite ~55% topline growth and triple digit EBITDA growth. WELL has multiple re-rate catalysts including WELLSTAR's planned IPO and potential US asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results